Tocilizumab

{
  "id": "MLC-T-ONC-008750",
  "term": "Tocilizumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults and children aged 2 years and older with severe or life-threatening cytokine release syndrome caused by a type of immunotherapy called chimeric antigen receptor (CAR) T-cell therapy. Tocilizumab is also used to treat certain types of arthritis and a condition that causes inflammation of the lining of the arteries. It is also being studied in the treatment of other conditions. Tocilizumab binds to receptors for a protein called interleukin-6 (IL-6), which is made by white blood cells and other cells in the body. This may help lower the body’s immune response and reduce inflammation. Tocilizumab is a type of monoclonal antibody. Also called Actemra.",
    "A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions."
  ],
  "abbreviation": "MRA",
  "synonyms": [
    "Actemra",
    "immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide with human-mouse monoclonal MRA kappa-chain, dimer"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tocilizumab/"
}